Literature DB >> 29966776

Childhood Lhermitte-Duclos Disease Progressing to Medulloblastoma in Bilateral Cerebellar Hemispheres: Report of Unusual Case.

Gautam Dutta1, Daljit Singh2, Ravindra Kumar Saran3, Hukum Singh2, Arvind Kumar Srivastava2, Anita Jagetia2.   

Abstract

BACKGROUND: Lhermitte-Duclos disease is an extremely rare pathologic entity characterized by a cerebellar mass composed of enlarged cerebellar folia containing abnormal ganglion cells. This entity usually presents in young and middle-aged adults and rarely in children. There is no study in the literature analyzing the long-term clinical course of this disease to assess the behavior primarily because of its rarity. CASE DESCRIPTION: We present our experience with a 7-year-old patient of Lhermitte-Duclos disease who was followed up for 5 years and found to have progressed to bilateral World Health Organization grade IV medulloblastoma. This case denotes the malignant potential of this rare disorder.
CONCLUSIONS: LDD is seen rarely and demands a high degree of suspicion in patients presenting with cerebellar mass and/or imaging characteristics. It is prudent to keep these patients in close follow-up for early detection of malignant transformation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Imaging; Lhermitte-Duclos disease; Medulloblastoma; Pediatrics

Mesh:

Year:  2018        PMID: 29966776     DOI: 10.1016/j.wneu.2018.06.161

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  2 in total

1.  Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos disease) presenting as a prenatally heterotopic hamartoma.

Authors:  Chloé Puiseux; Maxime Bretonnier; Maia Proisy; Céline Chappé; Philippe Denizeau; Laurent Riffaud
Journal:  Childs Nerv Syst       Date:  2020-07-03       Impact factor: 1.475

Review 2.  Toward Systems Pathology for PTEN Diagnostics.

Authors:  Nahal Haddadi; Glena Travis; Najah T Nassif; Ann M Simpson; Deborah J Marsh
Journal:  Cold Spring Harb Perspect Med       Date:  2020-05-01       Impact factor: 6.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.